Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis
Open Access
- 10 December 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (24) , 6237-6245
Abstract
Intracranial hemorrhage (ICH) and resulting neurologic disability are severe complications for a subset of infants with severe hemophilia A (HA). Although prophylactic factor replacement reduces bleeding risk, it is typically delayed until after age 1 year due to risks associated with central venous access placement. Emicizumab, a subcutaneous activated factor VIII (FVIII) mimetic, has demonstrated safety and efficacy in preventing ICH in infants aged <12 months in the HAVEN 7 trial. Despite its high cost, the cost-effectiveness of emicizumab prophylaxis initiated during the first year of life for infants with severe HA is not known. We developed a Markov cohort model to compare emicizumab prophylaxis to standard care (no prophylaxis) in infants aged 0 to 1 year with severe HA without FVIII inhibitors. The analysis was conducted from a US societal perspective over a lifetime horizon across all accepted willingness-to-pay (WTP) thresholds. The primary outcome was the incremental cost-effectiveness ratio (ICER) in US dollar per quality-adjusted life-year (QALY). Emicizumab prophylaxis and standard care accrued 25.6 and 25.1 QALYs at costs of $13.12 million and $13.07 million, respectively, resulting in an ICER of $99 900 per QALY (95% credible interval [CI], 84 000-120 000). Scenario analysis examining prophylaxis with low-dose emicizumab resulted in an ICER of $19 600 per QALY (95% CI, 12 000-29 000). Probabilistic sensitivity analyses showed that standard-dose emicizumab is the cost-effective strategy in 100%, 66%, and 0% of 10 000 Monte Carlo iterations at WTP thresholds of $150 000, $104 000, and $50 000 per QALY, respectively, and in 100% across all WTP thresholds for low-dose emicizumab.Keywords
This publication has 46 references indexed in Scilit:
- Developmental Expression of Drug Transporters and Conjugating Enzymes Involved in Enterohepatic Recycling: Implication for Pediatric Drug DosingClinical Pharmacology & Therapeutics, 2024
- Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patientsJournal of Thrombosis and Haemostasis, 2023
- Hemophilia A (Factor VIII Deficiency)Hematology/Oncology Clinics of North America, 2021
- HaemophiliaNature Reviews Disease Primers, 2021
- Incidence of inhibitor development in PUPs with severe Haemophilia A in the CEE region between 2005 and 2015Thrombosis Research, 2021
- Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018PharmacoEconomics, 2020
- Risk factors for inhibitor development in severe hemophilia AThrombosis Research, 2018
- Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical TrialsClinical Pharmacokinetics, 2018
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Hemophilia A in the third millenniumBlood Reviews, 2013